Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will ...

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, ...

On the first day of the J.P. Morgan Healthcare Conference, drug executives talked M&A, but also sized up the prospects of ...